GoodRx (NASDAQ:GDRX) PT Lowered to $6.00 at JPMorgan Chase & Co.

GoodRx (NASDAQ:GDRX) had its target price lowered by JPMorgan Chase & Co. from $7.00 to $6.00 in a research note issued to investors on Friday morning, Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the stock.

A number of other brokerages also recently issued reports on GDRX. Evercore ISI increased their target price on GoodRx from $7.00 to $10.00 and gave the stock an in-line rating in a research note on Thursday, August 10th. Deutsche Bank Aktiengesellschaft raised their target price on GoodRx from $6.00 to $8.00 and gave the company a hold rating in a report on Thursday, August 10th. Citigroup upped their price target on shares of GoodRx from $7.00 to $11.00 and gave the stock a buy rating in a research note on Thursday, August 10th. The Goldman Sachs Group reduced their price objective on shares of GoodRx from $7.00 to $6.00 and set a neutral rating for the company in a research note on Friday, November 10th. Finally, Royal Bank of Canada lowered their target price on shares of GoodRx from $8.00 to $5.00 and set a sector perform rating on the stock in a research report on Friday, November 10th. Nine research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of Hold and a consensus target price of $7.97.

GoodRx Stock Up 10.1 %

GoodRx stock opened at $5.76 on Friday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 8.23 and a current ratio of 8.23. The company has a market capitalization of $2.34 billion, a P/E ratio of 144.00, a PEG ratio of 5.41 and a beta of 1.17. The stock has a 50-day simple moving average of $5.39 and a 200-day simple moving average of $5.92. GoodRx has a fifty-two week low of $4.14 and a fifty-two week high of $9.37.

GoodRx (NASDAQ:GDRX) last issued its earnings results on Thursday, November 9th. The company reported $0.06 earnings per share for the quarter, meeting the consensus estimate of $0.06. The business had revenue of $180.00 million for the quarter, compared to the consensus estimate of $188.52 million. GoodRx had a net margin of 2.04% and a return on equity of 2.25%. The business’s quarterly revenue was down 3.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.07 earnings per share. Equities research analysts expect that GoodRx will post 0.08 earnings per share for the current year.

Insider Activity at GoodRx

In related news, insider Scott Wagner acquired 104,079 shares of GoodRx stock in a transaction on Thursday, November 16th. The shares were bought at an average price of $5.16 per share, for a total transaction of $537,047.64. Following the completion of the purchase, the insider now directly owns 104,079 shares in the company, valued at approximately $537,047.64. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.37% of the stock is owned by insiders.

Institutional Investors Weigh In On GoodRx

Large investors have recently added to or reduced their stakes in the company. National Bank of Canada FI grew its stake in shares of GoodRx by 207.3% during the second quarter. National Bank of Canada FI now owns 4,902 shares of the company’s stock valued at $27,000 after acquiring an additional 3,307 shares in the last quarter. Headlands Technologies LLC acquired a new stake in GoodRx during the 2nd quarter valued at approximately $29,000. New York Life Investment Management LLC purchased a new stake in GoodRx during the 1st quarter worth approximately $490,000. Gagnon Securities LLC raised its position in shares of GoodRx by 37.6% in the 2nd quarter. Gagnon Securities LLC now owns 48,015 shares of the company’s stock valued at $265,000 after purchasing an additional 13,115 shares in the last quarter. Finally, Harbor Capital Advisors Inc. purchased a new position in shares of GoodRx during the 2nd quarter valued at approximately $67,000. 33.63% of the stock is owned by institutional investors and hedge funds.

About GoodRx

GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.